Ascites Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Ascites Market Trends and Insights

Rising Cirrhosis And MASH-Linked Ascites Burden

The Ascites Market remains closely tied to the growing burden of advanced liver disease, with MASH-linked cirrhosis emerging as a key long-term demand driver. JAMA Network Open projected United States MASH cases to increase from 14.9 million in 2020 to 23.2 million by 2050, while MASH cirrhosis cases are projected to rise by 91.1%, from 1.147 million to 2.192 million. This is important because ascites is a common late-stage complication of cirrhosis, creating sustained demand for hospitalization, albumin use, imaging, drainage, and follow-up care.^{[1]JAMA Network Open, “Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050,” JAMA Network Open, jamanetwork.com} Liver Cancer International showed that total healthcare costs for MASH patients with cirrhosis were 1.3 to 2.7 times higher than for those without cirrhosis, while inpatient costs were as much as 13 times higher in decompensated disease than in compensated disease. China’s projected increase in the age-standardized Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-related cirrhosis burden through 2036 further strengthens the Asia-Pacific outlook and supports a broader treatment base in the region.

Repeat Paracentesis Demand In Refractory Ascites

The Ascites Market continues to gain from repeat procedure demand, as clinicians mainly manage refractory ascites through symptom control rather than durable reversal. Refractory Ascites held a 46.45% share in 2025, generating recurring hospital traffic through repeated large-volume paracentesis, albumin replacement, and ongoing monitoring. Current Hepatology Reports noted that each large-volume paracentesis session removes 21 g of protein per liter of ascitic fluid, contributing to malnutrition and sarcopenia.^{[2]Liver Cancer International, “The Economic Burden of Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis, A Systematic Review,” Liver Cancer International, doi.org} This reinforces recurring demand for kits, consumables, infusion therapies, and hospital services, especially where repeat drainage remains the standard pathway for late-stage patients. The REDUCe2 trial in England is comparing palliative long-term abdominal drains with hospital-based large-volume paracentesis, indicating that future demand may shift toward a more distributed care model rather than decline. The same treatment burden is also supporting earlier intervention discussions, which may move some revenue from late-stage repetitive procedures toward earlier interventional management.

Broader Use Of Albumin After Large-Volume Paracentesis

Broader and more clearly defined albumin use in routine care, particularly after paracentesis, continues to support the Ascites Market. The American Gastroenterological Association (AGA) Clinical Practice Update recommended 20-25% intravenous albumin at 6-8 g per liter removed after paracentesis exceeding 5 L. It also recommended considering albumin in lower-volume procedures when patients present with hypotension, renal insufficiency, or electrolyte abnormalities. This expands albumin use beyond a strict volume threshold and provides a clearer framework for repeated supportive therapy in higher-risk patients. The Chinese guidelines on the management of ascites in cirrhosis, published in 2024, also embedded intravenous albumin as protocol-standard therapy after large-volume paracentesis. These updates support stronger hospital adherence, formulary planning, standardized procurement, and repeat utilization, making supportive care a dependable revenue pillar for the Ascites Market.

First US Approval Of An Active Implantable Ascites Pump

The Ascites Market reached an important turning point when the United States approved the first active implantable pump for recurrent or refractory ascites due to liver cirrhosis. Sequana Medical received United States Food and Drug Administration (FDA) Premarket Approval for the alfapump in December 2024, creating the first Class III active implantable device in this care setting and offering a device-based alternative to repeated therapeutic drainage. The company reported in February 2026 that the POSEIDON study showed virtual elimination of therapeutic paracentesis and quality-of-life improvement at 6 and 24 months. It also reported that five United States centers had already completed implants since launch, with discussions active at more than 20 additional institutions. 

Limited Disease-Modifying Options For Root-Cause Reversal

A key structural restraint in the Ascites Market is the lack of a broadly approved therapy that can reverse the underlying disease process in established cirrhosis. The 2025 review in Annals of Hepatology found that long-term albumin can reduce the incidence of complications, but randomized evidence has not yet demonstrated a transplant-free survival benefit at the population level. This gap keeps the treatment pathway focused on symptom control and sustains demand through repeated treatment cycles. However, these cycles do not fully reset patient risk or materially shorten disease duration. Patients must still follow sodium restriction below 2,000 mg/day, undergo long diuretic titration periods, make repeat hospital visits, and receive ongoing monitoring. These requirements can weaken adherence and reduce the real-world effectiveness of standard care. As a result, the market continues to generate demand from chronic care but struggles to unlock the value expansion typically associated with durable therapeutic change. Until care moves beyond palliative control, the Ascites Market will continue to grow through higher volume and treatment intensity rather than a true transformation of the treatment pathway.

Procedure Dependence And Infection Risk In Long-Term Drainage

The Ascites Market also faces a practical restraint, as long-term drainage approaches can carry meaningful complication risks, particularly outside tightly managed specialist settings. The 2025 review published by Karger reported kidney injury in 17-50% of patients when drainage exceeded 1.5 liters per day, while catheter-related infections, including cellulitis and peritonitis, occurred in 7-58% of patients. These risks are significant because the market’s fastest-growing care settings depend on safe expansion beyond hospitals. However, infection management, antibiotic access, and timely clinical response vary across countries. This uneven access slows the scalability of home-based drainage models in cost-sensitive systems and limits the pace at which parts of the Ascites Market can shift toward lower-acuity care channels.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Treatment Type Anchors Revenue While Diagnostics Extend The Care Pathway

Treatment type is expected to account for 68.12% of the Ascites market size in 2025, showing that active management of fluid accumulation continues to drive commercial activity across the care pathway. This segment includes diuretics, paracentesis, albumin infusion, transjugular intrahepatic portosystemic shunt, liver transplantation, implantable pump therapy, and palliative long-term abdominal drainage. 

Diagnosis is projected to grow at a CAGR of 5.93% through 2031, making it the fastest-growing product category in the Ascites Market despite its smaller 2025 revenue base compared to treatment. Growth reflects a more protocol-driven care pathway supported by ultrasound-guided paracentesis, imaging-based quantification, and more consistent differential diagnosis. Regular disease monitoring increases diagnostic use, as each imaging touchpoint can support treatment selection, procedural planning, or complication follow-up. 

By Ascites Type: Refractory Dominates While Malignant Ascites Draws The Pipeline

Refractory ascites is expected to hold a 46.45% share in 2025, making it the largest type-based contributor to the Ascites Market and highlighting the revenue impact of late-stage patients. These patients often need repeated large-volume paracentesis, frequent albumin use, closer inpatient observation, and complex escalation decisions, which increases resource utilization. The clinical burden extends beyond fluid accumulation, as spontaneous bacterial peritonitis, hepatorenal syndrome, and repeat hospitalization often accompany refractory disease. This keeps the refractory patient pool central to the Ascites Market, especially in North America and Europe, where specialized hepatology infrastructure supports recurring procedural care at scale.

Malignant ascites is expected to advance at a CAGR of 6.67%, making it the fastest-growing type segment and one of the key innovation-led areas of the Ascites Market through 2031. Growth is expected to come from pipeline-led advances rather than only incremental improvements in drainage. A Phase III randomized trial of M701, an EpCAM×CD3 bispecific antibody administered intraperitoneally, is expected to report results at American Society of Clinical Oncology (ASCO) 2026, underscoring active development in malignant ascites. Multiple early-phase programs mentioned in the user draft, including autologous tumor-reactive T-cell and other biologic approaches, are positioning the intraperitoneal setting as a therapeutic target rather than only a drainage challenge.

By Route Of Administration: Parenteral Sustains Volume While Device-Based Delivery Redefines Care Boundaries

Parenteral administration is expected to hold 62.66% of the Ascites market size in 2025, reflecting the continued importance of intravenous albumin, inpatient diuretic use, and other hospital-based supportive interventions. This route remains dominant because albumin remains linked to large-volume paracentesis protocols, and many patients enter care when oral control is no longer adequate. Parenteral therapy also captures a sizable share of hospital admission value, as fluid management, complication control, and monitoring often occur together in higher-acuity settings. 

Device-based delivery is forecast to grow at a CAGR of 7.35%, the fastest pace among all routes, creating a meaningful shift in treatment delivery within the Ascites Market. The planned commercial launch of the alfapump from Q4 2025 is expected to give recurrent or refractory cases a technology-led option that can reduce reliance on repeat therapeutic paracentesis. Device-based care also has a clearer reimbursement pathway, as Centers for Medicare & Medicaid Services (CMS) support and procedure coding reduce adoption barriers for transplant and advanced hepatology centers. 

By End User: Hospitals Anchor Care While Home Settings Accelerate

Hospitals are expected to represent a 52.34% share in 2025, and they remain the leading end-user category in the Ascites Market because complex patients require specialist oversight, inpatient stabilization, and interventional escalation. Hospital systems manage the heaviest burden of refractory disease, spontaneous bacterial peritonitis, hepatorenal syndrome, implant procedures, and advanced imaging. They also influence purchasing decisions for albumin, paracentesis kits, drainage systems, and procedural support products through formulary and procurement structures. 

Home care settings are projected to grow at a CAGR of 6.78%, making them the fastest-growing end-user group in the Ascites Market as providers pursue lower-acuity and more patient-convenient care models. Growing support for palliative long-term abdominal drains and telehealth-guided follow-up indicates that home care is becoming a more recognized part of the care pathway. Even a partial migration of stable follow-up and selected drainage support can influence product mix and dispensing channels. 

By Distribution Channel: Hospital Pharmacy Dominates But Retail Disruption Is Underway

Hospital pharmacy is expected to hold 61.65% of the Ascites market size in 2025, consistent with a treatment pathway centered on inpatient care, infusion support, and hospital-administered therapies. This channel remains dominant because albumin, intravenous diuretics, and a large share of supportive medicines are tied to hospital episodes rather than routine community refills. Procurement concentration strengthens this role, as hospital systems often negotiate directly with suppliers and place volume through structured contracts. 

Retail pharmacy is projected to grow at a CAGR of 8.24%, the fastest among distribution channels, indicating a gradual outpatient shift in the Ascites Market. Stable cirrhosis patients who remain on oral diuretics or move through community-based follow-up naturally expand retail dispensing volume, provided adherence and monitoring can be maintained.

Geography Analysis

North America is expected to account for 39.56% of the ascites market share in 2025, making it the largest regional contributor and reinforcing its position as the commercial center of the ascites market. The United States leads the region, supported by advanced hepatology networks, high procedural capacity, strong hospital purchasing systems, and the first approved active implantable device for recurrent or refractory cirrhotic ascites. The expected alfapump launch in the fourth quarter (Q4) of 2025 is set to add a device-backed treatment option to the US care pathway and reduce reliance on repeated drainage. Centers for Medicare & Medicaid Services (CMS) New Technology Add-on Payment support, effective October 1, 2025, is expected to improve inpatient reimbursement and support hospital adoption.

Europe represents the second major regional block in the ascites market, backed by established hepatology practice, broad use of paracentesis and albumin, and relevant experience with device-led care. Germany, the United Kingdom, France, Italy, Spain, and the rest of Europe support a structured care environment for advanced liver disease through specialist referrals and hospital-based management. Prior familiarity with the alfapump under European approval pathways gives the region a clinical base for future uptake where reimbursement and patient selection align. The REDUCe2 trial in the United Kingdom is expected to provide health-system evidence on palliative long-term abdominal drains and may influence procurement in home-oriented care models.

Asia-Pacific is forecast to expand at a CAGR of 8.56%, making it the fastest-growing regional part of the ascites market through 2031. Large hepatitis B and hepatitis C patient pools, the continuing burden of alcohol-related liver disease, and improving interventional radiology capacity support regional growth. India remains a key market, with 40 million people affected by hepatitis B, 12 million affected by hepatitis C, and the Ayushman Bharat program reaching 500 million people, supporting broader access to hepatology services. China is also important, as a 2025 trial in Gut showed that rice-derived recombinant human serum albumin performed comparably to plasma-derived albumin in decompensated cirrhosis, with implications for supply and cost dynamics.